特发性声门下狭窄的比较治疗结局:5年更新
北美气道协作组(NoAAC)对487例特发性声门下狭窄(iSGS)患者进行为期5年的前瞻性多中心队列观察,比较三种主要手术技术的治疗有效性。环气管切除的再次手术率最低(5%),内镜下切除联合辅助药物治疗为30%,内镜下扩张为50%。数据支持初始观察结果,为医患纵向决策提供依据。
要点
- 5年观察显示iSGS治疗有效性因治疗方式而异。
- 环气管切除再次手术率最低(5%),内镜切除联合药物治疗为30%,内镜扩张为50%。
- 证据等级为2级前瞻性队列研究。
核心结论
- 5年前瞻性观察显示iSGS治疗有效性因治疗方式而异。
- 环气管切除再次手术率最低(5%),内镜切除联合辅助药物治疗为30%,内镜扩张为50%。
- 数据支持初始观察结果,并为医患纵向决策提供价值。
研究设计与样本
- 北美气道协作组(NoAAC)多机构前瞻性队列研究,487例iSGS患者再入组额外2年并按预设方案随访至5年。
主要发现
- 治疗有效性因治疗方式而异:环气管切除再次手术率为5%,内镜切除联合辅助药物治疗为30%,内镜扩张为50%。
关键数值与推荐
- 环气管切除再次手术率为5%。
- 内镜切除联合辅助药物治疗再次手术率为30%。
- 内镜扩张再次手术率为50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The North American Airway Collaborative (NoAAC) previously published a 3-year multi-institutional prospective cohort study showing variation in treatment effectiveness between 3 primary surgical techniques for idiopathic subglottic stenosis (iSGS). In this report, we update these findings to include 5 years of data evaluating treatment effectiveness. Patients in the NoAAC cohort were re-enrolled for 2 additional years and followed using the prespecified published protocol. Consistent with prior data, prospective observation of 487 iSGS patients for 5 years showed treatment effectiveness differed by modality. Cricotracheal resection maintained the lowest rate of recurrent operation (5%), followed by endoscopic resection with adjuvant medical therapy (30%) and endoscopic dilation (50%). These data support the initial observations and continue to provide value to providers and patients navigating longitudinal decision-making. Level of evidence: 2-prospective cohort study.
引用
- Tierney WS, Huang LC, Chen SC, et al. Comparative Treatment Outcomes for Idiopathic Subglottic Stenosis: 5-Year Update. Otolaryngol Head Neck Surg. 2023. PMID: 36939627. doi:10.1002/ohn.190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。